Emerging biomarkers for heart failure: An update

Biomarkers in Medicine

Volumn 8, Issue 6, 2014, Pages 833-840

  Dalzell, Jonathan R ^a   Cannon, Jane A ^b   Jackson, Colette E ^a   Lang, Ninian N ^a   Gardner, Roy S ^a  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

biomarkers; emerging; heart failure; novel

Indexed keywords

ACE2 PEPTIDASE; ALPHA DEFENSIN; AMINOPEPTIDASE; BIOLOGICAL MARKER; ENDOGLIN; FOLLISTATIN; FOLLISTATIN LIKE 1; GLYCOPROTEIN; LEUCINE RICH ALPHA 2 GLYCOPROTEIN; MIDKINE; PANCREATITIS ASSOCIATED PROTEIN; PROTEIN; S100A8 A9; SECONDARY LYMPHOID TISSUE CHEMOKINE; SYNDECAN 4; TENASCIN; UNCLASSIFIED DRUG;

HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; REPERFUSION INJURY; REVIEW; BLOOD;

BIOLOGICAL MARKERS; HEART FAILURE; HUMANS;

EID: 84907274369     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.51     Document Type: Review

References (69)

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 93, 1137-1146 (2007).
2. Dalzell JR, Jackson CE, McDonagh TA, Gardner RS. Novel biomarkers in heart failure: an overview. Biomark. Med. 3, 453-463 (2009).
3. Nishioka T, Onishi K, Shimojo N et al. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am. J. Physiol. Heart Circ. Physiol. 298, H1072-H1078 (2010).
4. Sato A, Aonuma K, Imanaka-Yoshida K et al. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J. Am. Coll. Cardiol. 47, 2319-2325 (2006).
5. Liabeuf S, Barreto DV, Kretschmer A et al. High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. Atherosclerosis 215, 116-124 (2011).
6. Imanaka-Yoshida K, Hiroe M, Yasutomi Y et al. Tenascin-C is a useful marker for disease activity in myocarditis. J. Pathol. 197, 388-394 (2002).
7. Morimoto S, Imanaka-Yoshida K, Hiramitsu S et al. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J. Pathol. 205, 460-467 (2005).
8. Aso N, Tamura A, Nasu M. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. Am. J. Cardiol. 94, 1468-1470 (2004).
9. Kitaoka H, Kubo T, Baba Y et al. Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy. J. Cardiol. 59, 209-214 (2012).
10. Sato A, Hiroe M, Akiyama D et al. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction. J. Card. Fail. 18, 480-486 (2012).
11. Terasaki F, Okamoto H, Onishi K et al. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ. J. 71, 327-330 (2007).
12. Fujimoto N, Onishi K, Sato A et al. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J. Card. Fail. 15, 898-905 (2009).
13. Yao HC, Han QF, Zhao AP, Yao DK, Wang LX. Prognostic values of serum tenascin-C in patients with ischaemic heart disease and heart failure. Heart Lung Circ. 22, 184-187 (2013).
14. Hessel MH, Bleeker GB, Bax JJ et al. Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur. J. Heart Fail. 9, 1058-1063 (2007).
15. Shibanuma M, Mashimo J, Mita A, Kuroki T, Nose K. Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur. J. Biochem. 217, 13-19 (1993).
16. Kawabata D, Tanaka M, Fujii T et al. Ameliorative effects of follistatin-related protein/TSC-36/FSTL1 on joint inflammation in a mouse model of arthritis. Arthritis Rheum. 50, 660-668 (2004).
17. Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 117, 3099-3108 (2008).
18. El-Armouche A, Ouchi N, Tanaka K et al. Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling. Circ. Heart Fail. 4, 621-627 (2011).
19. Finsen AV, Woldbaek PR, Li J et al. Increased syndecan expression following myocardial infarction indicates a role in cardiac remodeling. Physiol. Genomics 16, 301-308 (2004).
20. Finsen AV, Lunde IG, Sjaastad I et al. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway. PLoS ONE 6, e28302 (2011).
21. Matsui Y, Ikesue M, Danzaki K et al. Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ. Res. 108, 1328-1339 (2011).
22. Echtermeyer F, Harendza T, Hubrich S et al. Syndecan-4 signalling inhibits apoptosis and controls NFAT activity during myocardial damage and remodelling. Cardiovasc. Res. 92, 123-131 (2011).
23. Strand ME, Herum KM, Rana ZA et al. Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart. FEBS J. 280, 2228-2247 (2013).
24. Kojima T, Takagi A, Maeda M et al. Plasma levels of syndecan-4 (ryudocan) are elevated in patients with acute myocardial infarction. Thromb. Haemost. 85, 793-799 (2001).
25. Takahashi R, Negishi K, Watanabe A et al. Serum syndecan-4 is a novel biomarker for patients with chronic heart failure. J. Cardiol. 57, 325-332 (2011).
26. Bielecka-Dabrowa A, von Haehling S, Aronow WS, Ahmed MI, Rysz J, Banach M. Heart failure biomarkers in patients with dilated cardiomyopathy. Int. J. Cardiol. 168, 2404-2410 (2013).
27. Netsu S, Shishido T, Kitahara T et al. Midkine exacerbates pressure overload-induced cardiac remodeling. Biochem. Biophys. Res. Commun. 443, 205-210 (2014).
28. Kitahara T, Shishido T, Suzuki S et al. Serum midkine as a predictor of cardiac events in patients with chronic heart failure. J. Card. Fail. 16, 308-313 (2010).
29. Przybylowski P, Malyszko J, Malyszko JS. Serum midkine is related to NYHA class and cystatin C in heart transplant recipients. Transplant Proc. 42, 3704-3707 (2010).
30. Yndestad A, Finsen AV, Ueland T et al. The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure. PLoS ONE 7, e33038 (2012).
31. Ueland T, Nymo SH, Latini R et al. Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial; Investigators of the GISSI-Heart Failure (GISSI-HF) trial. CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. Eur. J. Heart Fail. 15, 747-755 (2013).
32. Volz HC, Laohachewin D, Seidel C et al. S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-κB signaling. Basic Res. Cardiol. 107, 250 (2012).
33. Ma LP, Haugen E, Ikemoto M, Fujita M, Terasaki F, Fu M. S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. Int. J. Cardiol. 155, 26-32 (2012).
34. Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87, e1-e9 (2000).
35. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838-14843 (2002).
36. Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ. Res. 98, 463-471 (2006).
37. Lambert DW, Yarski M, Warner FJ et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 280, 30113-30119 (2005).
38. Crackower MA, Sarao R, Oudit GY et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828 (2002).
39. Nakamura K, Koibuchi N, Nishimatsu H et al. Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice. Hypertens. Res. 31, 1953-1961 (2008).
40. Gurley SB, Allred A, Le TH et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J. Clin. Invest. 116, 2218-2225 (2006).
41. Kassiri Z, Zhong J, Guo D et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ. Heart Fail. 2, 446-455 (2009).
42. Yamamoto K, Ohishi M, Katsuya T et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47, 718-726 (2006).
43. Huentelman MJ, Grobe JL, Vazquez J et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp. Physiol. 90, 783-790 (2005).
44. Der Sarkissian S, Grobe JL, Yuan L et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51, 712-718 (2008).
45. Johnson JA, West J, Maynard KB, Hemnes AR. ACE2 improves right ventricular function in a pressure overload model. PLoS ONE 6, e20828 (2011).
46. Burrell LM, Risvanis J, Kubota E et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J. 26, 369-375 (2005).
47. Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2, 19 (2004).
48. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605-2610 (2005).
49. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43, 970-976 (2004).
50. Kaiqiang Ji, Minakawa M, Fukui K, Suzuki Y, Fukuda I. Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. Ther. Adv. Cardiovasc. Dis. 3, 103-111 (2009).
51. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J. Am. Coll. Cardiol. 52, 750-754 (2008).
52. Epelman S, Shrestha K, Troughton RW et al. Soluble angiotensin-converting enzyme 2 in human heart failure:relation with myocardial function and clinical outcomes. J. Card. Fail. 15, 565-571 (2009).
53. Wang Y, Moreira Mda C, Heringer-Walther S et al. Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. J. Card. Fail. 16, 157-163 (2010).
54. Shao Z, Shrestha K, Borowski AG et al. Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure. J. Card. Fail. 19, 605-610 (2013).
55. Bdeir K, Cane W, Canziani G et al. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 94, 2007-2019 (1999).
56. Christensen HM, Frystyk J, Faber J et al. α-defensins and outcome in patients with chronic heart failure. Eur. J. Heart Fail. 14, 387-394 (2012).
57. Closa D, Motoo Y, Iovanna JL. Pancreatitis-associated protein: from a lectin to an anti-inflammatory cytokine. World J. Gastroenterol. 13, 170-174 (2007).
58. Rouquier S, Verdier JM, Iovanna J, Dagorn JC, Giorgi D. Rat pancreatic stone protein messenger RNA. Abundant expression in mature exocrine cells, regulation by food content, and sequence identity with the endocrine reg transcript. J. Biol. Chem. 266, 786-791 (1991).
59. Watanabe R, Hanawa H, Yoshida T et al. Gene expression profiles of cardiomyocytes in rat autoimmune myocarditis by DNA microarray and increase of regenerating gene family. Transl. Res. 152, 119-127 (2008).
60. Fitzgibbons TP, Paolino J, Dagorn JC, Meyer TE. Usefulness of pancreatitis-associated protein, a novel biomarker, to predict severity of disease in ambulatory patients with heart failure. Am. J. Cardiol. 113, 123-126 (2014).
61. Ai J, Druhan LJ, Hunter MG, Loveland MJ, Avalos BR. LRG-accelerated differentiation defines unique G-CSFR signaling pathways downstream of PU.1 and C/EBPepsilon that modulate neutrophil activation. J. Leukoc. Biol. 83, 1277-1285 (2008).
62. Codina R, Vanasse A, Kelekar A, Vezys V, Jemmerson R. Cytochrome c-induced lymphocyte death from the outside in: inhibition by serum leucine-rich alpha-2-glycoprotein-1. Apoptosis 15, 139-152 (2010).
63. O'Donnell LC, Druhan LJ, Avalos BR. Molecular characterization and expression analysis of leucine-rich alpha2-glycoprotein, a novel marker of granulocytic differentiation. J. Leukoc. Biol. 72, 478-485 (2002).
64. Shirai R, Hirano F, Ohkura N, Ikeda K, Inoue S. Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem. Biophys. Res. Commun. 382, 776-779 (2009).
65. Watson CJ, Ledwidge MT, Phelan D et al. Proteomic analysis of coronary sinus serum reveals leucine-rich alpha2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Circ. Heart Fail. 4, 188-197 (2011).
66. Heffernan KS, Kuvin JT, Patel AR, Karas RH, Kapur NK. Endothelial function and soluble endoglin in smokers with heart failure. Clin. Cardiol. 34, 729-733 (2011).
67. Kapur NK, Heffernan KS, Yunis AA et al. Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am. J. Cardiol. 106, 1770-1776 (2010).
68. Pfisterer M, Buser P, Rickli H et al. TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301, 383-392 (2009).
69. Lainchbury JG, Troughton RW, Strangman KM et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J. Am. Coll. Cardiol. 55, 53-60 (2009).